Last edition
News about "clinical trial "
Ractigen Therapeutics Doses First Patient in Phase I Clinical Trial for RAG-17 in SOD1-ALS
RAG-17 received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) in March 2023, followed by the FDA's clearance of its Investigational New Drug (IND) application.
Clinical Trial | 26/12/2024 | By Aishwarya
Antag Therapeutics Gets FDA Clearance IND Application for AT-7687
The study will also explore AT-7687 as a monotherapy and in combination with semaglutide, a GLP-1 receptor agonist, in healthy obese individuals.
Clinical Trial | 09/10/2024 | By Aishwarya
AbbVie Gets Positive CHMP Opinion for Mirvetuximab Soravtansine
AbbVie has announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorization of mirvetuximab soravtansine (ELAHERE).
Clinical Trial | 21/09/2024 | By Aishwarya | 112
Mabwell Gets CDE Approval to Initiate Phase III Clinical Trial of 9MW2821
9MW2821 is a novel Nectin-4-targeting ADC independently developed by Mabwell, and it is the first of its kind in China to initiate clinical trials on the same target, with more than 400 subjects enrolled in the clinical studies for multiple indications.
Clinical Trial | 27/08/2024 | By Aishwarya
Mabwell Gets NMPA Approval for Clinical Trial of Nectin-4 Targeting ADC in TNBC
Mabwell has announced that its novel Nectin-4 targeting ADC has been approved by the NMPA to enter Phase II clinical trial as monotherapy or in combination with a PD-1 inhibitor for the treatment of triple-negative breast cancer (TNBC).
Clinical Trial | 16/07/2024 | By Aishwarya
Sen-Jam Pharma Completes Enrollment for Phase 2 URIs or COVID
Sen-Jam Pharmaceutical has completed participant enrollment for the clinical trial of its innovative therapeutic, SJP-002C in partnership with Duke University.
Clinical Trial | 25/06/2024 | By Aishwarya | 139
FDA Grants IND Approval for Lomonitinib to Eilean Therapeutics
Eilean Therapeutics has announced that the US Food and Drug Administration (FDA) has cleared the IND for lomonitinib (ZE46-0134).
Clinical Trial | 11/06/2024 | By Aishwarya | 243
Nxera Pharma to Receive USD 4.6 Million from Centessa
Nxera Pharma has been expecting to receive USD 4.6 million in milestone payments from Centessa Pharmaceuticals under a license agreement regarding Nxera technology used to help design Centessa’s novel orexin receptor 2 (OX2R) agonist, ORX750.
Clinical Trial | 30/05/2024 | By Aishwarya | 112
NS Pharma Reports Preliminary Results of Viltolarsen Phase 3 Clinical Trial
NS Pharma, Inc. has received preliminary analysis results from the global Phase 3 clinical trial (RACER53 study, NCT04060199) of NS-065/NCNP-01.
Clinical Trial | 28/05/2024 | By Aishwarya
Acumen Announces First Patient Dosed in ALTITUDE-AD
Acumen Pharmaceuticals, Inc. has announced that the first patient has been dosed with sabirnetug (ACU193) in the ALTITUDE-AD Phase 2 clinical trial designed to evaluate the clinical efficacy and safety of sabirnetug in patients with early AD.
Clinical Trial | 08/05/2024 | By Aishwarya | 124
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy